Literature DB >> 23677793

Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study.

Nancy E Lane1, Neeta Parimi, Maripat Corr, Wei Yao, Jane A Cauley, Carrie M Nielson, Joseph H Ix, Deborah Kado, Eric Orwoll.   

Abstract

Normal mineral metabolism is critical for skeletal integrity, and recently serum fibroblast growth factor 23 (FGF23) levels were found to be directly related to overall fracture risk in elderly Swedish men. To confirm this association, we performed a prospective case-cohort study to understand the relation of FGF23 and fracture risk in older white men enrolled in the Osteoporotic Fractures in Men (MrOS) study. In the cohort of 5994 men attending the baseline MrOS examination, we evaluated a subgroup of 387 men with incident nonvertebral fracture including 73 hip fractures and a sample of 1385 men randomly selected from the cohort with baseline mineral and calcium hormone measurements. FGF23 was measured in baseline serum samples by ELISA (Millipore, Billerica, MA, USA). Modified Cox proportional hazards models that account for case-cohort study design were used to estimate the relative hazards (RH) of fracture in men across quartiles of FGF23. Subjects were also stratified by renal function, and RH per strata was estimated in men with the highest quartile of FGF23 compared with quartiles 3, 2, and 1. Overall, there was no difference in risk of nonspine or hip fracture by baseline FGF23. However, associations differed by strata of eGFRCrCy . Among men with eGFRCrCys <60 mL/min/1.73 m2 (n = 73/313 nonspine fractures), the RH in the highest quartile of FGF23 compared with the rest was 2.02 (95% confidence interval [CI] 1.07-3.79), but in men with eGFRCrCy , >60 mL/min/1.73 m2 (304/1370 fractures) the RH was 0.91 (95% CI 0.66-1.25) after adjustment for age, clinic site, body mass index, race, total hip bone mineral density, vitamin D, parathyroid hormone, alcohol use, physical activity, fracture history, and serum phosphorus. Serum FGF23 levels are not associated with incident fractures in elderly men overall. However, higher levels of serum FGF23 are associated with fracture risk in those with poor renal function.
© 2013 American Society for Bone and Mineral Research.

Entities:  

Keywords:  FGF23; MEN; OSTEOPOROSIS

Mesh:

Substances:

Year:  2013        PMID: 23677793      PMCID: PMC3805817          DOI: 10.1002/jbmr.1985

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  30 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone.

Authors:  Nancy S Krieger; Christopher D Culbertson; Kelly Kyker-Snowman; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

3.  Estimating glomerular filtration rate from serum creatinine and cystatin C.

Authors:  Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey
Journal:  N Engl J Med       Date:  2012-07-05       Impact factor: 91.245

4.  Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

Authors:  Junichiro J Kazama; Fuminori Sato; Kentaro Omori; Hitomi Hama; Suguru Yamamoto; Hiroki Maruyama; Ichiei Narita; Fumitake Gejyo; Takeyoshi Yamashita; Seiji Fukumoto; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

5.  Serum FGF23 levels in normal and disordered phosphorus homeostasis.

Authors:  Thomas J Weber; Shiguang Liu; Olafur S Indridason; L Darryl Quarles
Journal:  J Bone Miner Res       Date:  2003-07       Impact factor: 6.741

6.  Evaluation of the Dade Behring N Latex Cystatin C assay on the Dade Behring Nephelometer II System.

Authors:  E J Erlandsen; E Randers; J H Kristensen
Journal:  Scand J Clin Lab Invest       Date:  1999-02       Impact factor: 1.713

Review 7.  FGF23 production by osteocytes.

Authors:  Lynda F Bonewald; Michael J Wacker
Journal:  Pediatr Nephrol       Date:  2012-09-16       Impact factor: 3.714

8.  Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.

Authors:  Simon Wöhrle; Christine Henninger; Olivier Bonny; Anne Thuery; Noemie Beluch; Nancy E Hynes; Vito Guagnano; William R Sellers; Francesco Hofmann; Michaela Kneissel; Diana Graus Porta
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

9.  Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis The Study of Osteoporotic Fractures Research Group.

Authors:  H K Genant; M Jergas; L Palermo; M Nevitt; R S Valentin; D Black; S R Cummings
Journal:  J Bone Miner Res       Date:  1996-07       Impact factor: 6.741

10.  Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.

Authors:  Tobias Larsson; Richard Marsell; Ernestina Schipani; Claes Ohlsson; Osten Ljunggren; Harriet S Tenenhouse; Harald Jüppner; Kenneth B Jonsson
Journal:  Endocrinology       Date:  2004-02-26       Impact factor: 4.736

View more
  21 in total

1.  FGF23-klotho axis, bone fractures, and arterial stiffness in dialysis: a case-control study.

Authors:  L-C Desbiens; A Sidibé; R-V Ung; C Fortier; M Munger; Y-P Wang; S-K Bisson; K Marquis; M Agharazii; F Mac-Way
Journal:  Osteoporos Int       Date:  2018-06-29       Impact factor: 4.507

2.  Checkpoint kinase Chk2 controls renal Cyp27b1 expression, calcitriol formation, and calcium-phosphate metabolism.

Authors:  Hajar Fahkri; Bingbing Zhang; Abul Fajol; Nati Hernando; Bernat Elvira; Julia G Mannheim; Bernd J Pichler; Christoph Daniel; Kerstin Amann; Atsushi Hirao; Jillian Haight; Tak W Mak; Florian Lang; Michael Föller
Journal:  Pflugers Arch       Date:  2014-10-17       Impact factor: 3.657

3.  Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones.

Authors:  Eric N Taylor; Andrew N Hoofnagle; Gary C Curhan
Journal:  Clin J Am Soc Nephrol       Date:  2015-01-26       Impact factor: 8.237

Review 4.  The Utility of Biomarkers in Osteoporosis Management.

Authors:  Patrick Garnero
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

5.  High FGF23 levels are associated with impaired trabecular bone microarchitecture in patients with osteoporosis.

Authors:  T Rupp; S Butscheidt; E Vettorazzi; R Oheim; F Barvencik; M Amling; T Rolvien
Journal:  Osteoporos Int       Date:  2019-05-01       Impact factor: 4.507

6.  Serum fibroblast growth factor 23, serum iron and bone mineral density in premenopausal women.

Authors:  Erik A Imel; Ziyue Liu; Amie K McQueen; Dena Acton; Anthony Acton; Leah R Padgett; Munro Peacock; Michael J Econs
Journal:  Bone       Date:  2016-03-08       Impact factor: 4.398

7.  FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls.

Authors:  Deborah M Mitchell; Harald Jüppner; Sherri-Ann M Burnett-Bowie
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

8.  Associations of 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D With Bone Mineral Density, Bone Mineral Density Change, and Incident Nonvertebral Fracture.

Authors:  Christine M Swanson; Priya Srikanth; Christine G Lee; Steven R Cummings; Ivo Jans; Jane A Cauley; Roger Bouillon; Dirk Vanderschueren; Eric S Orwoll; Carrie M Nielson
Journal:  J Bone Miner Res       Date:  2015-05-22       Impact factor: 6.741

9.  Dietary factors and fibroblast growth factor-23 levels in young adults with African ancestry.

Authors:  Dominique Kosk; Holly Kramer; Amy Luke; Pauline Camacho; Pascal Bovet; Jacob Plange Rhule; Terrence Forrester; Myles Wolf; Chris Sempos; Michal L Melamed; Lara R Dugas; Richard Cooper; Ramon Durazo-Arvizu
Journal:  J Bone Miner Metab       Date:  2016-12-09       Impact factor: 2.626

10.  Associations of FGF23 With Change in Bone Mineral Density and Fracture Risk in Older Individuals.

Authors:  Tamara Isakova; Xuan Cai; Jungwha Lee; Ronit Katz; Jane A Cauley; Linda F Fried; Andrew N Hoofnagle; Suzanne Satterfield; Tamara B Harris; Michael G Shlipak; Mark J Sarnak; Joachim H Ix
Journal:  J Bone Miner Res       Date:  2015-12-23       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.